# Dr. Reddy's Laboratories (NSE: DRREDDY) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DRREDDY · Pivot · prices to 21 Oct 2026

Dr. Reddy's Laboratories (NSE: DRREDDY) closed at ₹1,240.50 on 21 Oct 2026. With a market capitalisation of ₹1,03,600 Cr, it ranks 101st by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

At its last close the stock traded at 25× trailing earnings, against a return on equity of 11.1% in FY26. Over the past year the share price has fallen 1.8%. Its 52-week range is ₹1,101.00 (23 Jul 2026) to ₹1,414.90 (29 Jun 2026); the last close is 12.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹8,071 Cr (−5.6% year on year) and net profit ₹435 Cr (−69.2%), on a consolidated basis. Promoters held 26.64% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,240.50 |
| Market cap | ₹1,03,600 Cr |
| P/E (trailing) | 25 |
| ROE | 11.1% (FY26) |
| ROCE | 13.9% (FY26) |
| Debt to equity | 0.17 |
| 52-week high | ₹1,414.90 (29 Jun 2026) |
| 52-week low | ₹1,101.00 (23 Jul 2026) |
| 1-year return | −1.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹8,071 Cr | −5.6% | ₹435 Cr | −69.2% | ₹5.33 |
| Q4 FY26 | ₹7,516 Cr | −11.6% | ₹217 Cr | −86.3% | ₹2.65 |
| Q3 FY26 | ₹8,727 Cr | +4.1% | ₹1,187 Cr | −15.2% | ₹14.53 |
| Q2 FY26 | ₹8,805 Cr | +9.5% | ₹1,331 Cr | −0.4% | ₹16.18 |
| Q1 FY26 | ₹8,545 Cr | +11.0% | ₹1,410 Cr | +1.7% | ₹17.04 |
| Q4 FY25 | ₹8,506 Cr | +20.1% | ₹1,581 Cr | +21.0% | ₹19.12 |
| Q3 FY25 | ₹8,381 Cr | +15.8% | ₹1,400 Cr | +1.6% | ₹16.97 |
| Q2 FY25 | ₹8,038 Cr | +16.5% | ₹1,336 Cr | −9.6% | ₹80.45 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹33,700 Cr | ₹4,144 Cr |
| FY25 | ₹32,644 Cr | ₹5,704 Cr |
| FY24 | ₹28,011 Cr | ₹5,563 Cr |
| FY23 | ₹24,670 Cr | ₹4,470 Cr |
| FY22 | ₹21,545 Cr | ₹2,112 Cr |
| FY21 | ₹19,048 Cr | ₹1,904 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 26.64%
- Foreign institutions: 32.07%
- Domestic institutions: 31.74%
- Non-institutions: 9.35%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,061.90 | ₹1,11,394 Cr | 124.8 | 8.0% |
| [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,111.50 | ₹1,10,873 Cr | 22.2 | 18.6% |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,695.00 | ₹1,10,642 Cr | 57 | 20.5% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,324.00 | ₹1,06,959 Cr | 27.5 | 11.3% |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,617.00 | ₹93,039 Cr | 26.8 | 9.2% |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,251.00 | ₹92,965 Cr | 48.7 | 11.7% |

## Questions and answers

### What is the share price of Dr. Reddy's Laboratories today?

Dr. Reddy's Laboratories (NSE: DRREDDY) last closed at ₹1,240.50 on 21 Oct 2026. Its 52-week high is ₹1,414.90 and its 52-week low is ₹1,101.00.

### What is the market cap of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' market capitalisation is ₹1,03,600 Cr (₹1.04 lakh Cr) at the 19 Oct 2026 close, ranking 101st among the NSE companies Pivot tracks.

### What is the P/E ratio of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories trades at a trailing P/E of 25. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.7.

### What is the ROE and ROCE of Dr. Reddy's Laboratories?

Return on equity was 11.1% in FY26 and return on capital employed was 13.9% in FY26 (consolidated figures).

### Is Dr. Reddy's Laboratories a debt-free company?

No. Dr. Reddy's Laboratories' debt-to-equity ratio was 0.17 in FY26, with total debt of ₹0 Cr.

### What were Dr. Reddy's Laboratories' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Reddy's Laboratories reported revenue of ₹8,071 Cr, −5.6% year on year, and net profit of ₹435 Cr, −69.2% year on year.

### How has Dr. Reddy's Laboratories stock performed over the last year?

Dr. Reddy's Laboratories' share price has fallen 1.8% over the past year, +1.6% over three months and +5.6% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Dr. Reddy's Laboratories?

As of 30 Jun 2026: promoters 26.64%, foreign institutions 32.07%, domestic institutions 31.74%, non-institutions 9.35%.

### Who are Dr. Reddy's Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Dr. Reddy's Laboratories by market cap are Laurus Labs, Zydus Lifesciences, Apollo Hospitals Enterprise, Cipla, Aurobindo Pharma and Mankind Pharma.

### Is Dr. Reddy's Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dr. Reddy's Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DRREDDY against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.